(2010) Dopamine receptors and behavior: from psychopharmacology to mutant models
93,94,95,96 Advancements in carrier technology and nucleic acid modification techniques have led to significant progress in overcoming these challenges, as exemplified by the first siRNA drug, patisiran (Onpattro), which has been approved for treating hereditary transthyretin-mediated amyloidosis by degrading mRNA encoding transthyretin (TTR)
Lancet (London, England) , 354 , 740741
Here, we highlight another factor, lack of standardized technique, which may also contribute to translational failure
doi: 10.1136/gutjnl-2018-318126 30 KalisperatiPSpanouEPaterasISKorkolopoulouPVarvarigouAKaravokyrosIet al
- Sun protecting: For your AM routine, a broad-spectrum sunscreen is non-negotiable